LEO Pharma

News

Blue sky with white clouds and bright sunlight

LEO Pharma pens $435m deal for Tanabe Pharma’s dersimelagon

LEO Pharma is betting up to $435m on a pill that could give people with an ultra-rare light sensitivity disorder a way to spend more time outdoors.

News

LEO bulks up with deal for Boehringer skin drug

LEO Pharma has licensed a medicine for a rare form of psoriasis from Boehringer Ingelheim, plugging a gap in its near-term product portfolio.

News

LEO launches chronic hand eczema drug in its first market

Germany has become the debut market for LEO Pharma's Anzupgo, the first topical treatment specifically approved for chronic hand eczema (CHE).

News

Rare disease drug from LEO's Timber felled by failed study

Just a few months after buying Timber Pharma, LEO Pharma has revealed that the main drug it acquired as part of the deal has failed a phase 3 trial.

News

physician holds hand of a person with chronic hand eczema

LEO closes on first approval for chronic hand eczema drug

Danish dermatology specialist LEO Pharma could be just weeks away from EU approval for delgocitinib, a treatment for chronic hand eczema (CHE) considered to be its top pipeline prospect.

News

Survey reveals heavy burden of chronic hand eczema

People with chronic hand eczema (CHE) have reported the serious impact the condition can have on their daily lives in a UK survey.

LEO Pharma pens $435m deal for Tanabe Pharma’s dersimelagon

LEO bulks up with deal for Boehringer skin drug

LEO launches chronic hand eczema drug in its first market

Rare disease drug from LEO's Timber felled by failed study

LEO closes on first approval for chronic hand eczema drug

Survey reveals heavy burden of chronic hand eczema

ESC26: Isomab safety evidence on blood vessel growth for CAD

Discover a new era of healthcare panel engagement: Grounded ...

LEO Pharma

Editor's Picks